In this article, Andrew Tepperman discusses a set of specific liability and damages issues that could be addressed by economic and business expert testimony. The context is assumed to be an international arbitration proceeding involving firms in the pharmaceutical industry. This article appeared in the 2015 edition of The International Comparative Legal Guide to: International Arbitration, published by Global Legal Group Ltd, London. To read the article, click the link below.
Looking ahead to 2026: Trends and expectations for International Arbitration
Across both investor-state and commercial cases, quantum debates have recently turned on attribution under concurrent shocks, the interaction of contract terms...